Silexion Therapeutics Reports Positive Preclinical Findings for SIL204

Grand Cayman, Cayman Islands, Sept. 28, 2026 /CourierPR/ -- Silexion Therapeutics, a clinical-stage biotechnology company, has announced positive findings from its ongoing translational research program. The study, which is part of the company's Phase 2/3 clinical development, demonstrates that its lead candidate, SIL204, effectively harnesses naturally occurring circulating lipoproteins to achieve intracellular delivery and drive potent, dose-dependent knockdown of mutant KRAS oncogene expression in cancer cells.

The research, conducted in a carrier-free, non-transfection assay without synthetic transfection reagents, showed that human KRAS-driven cancer cells treated with SIL204 exhibited robust, dose-dependent gene silencing in the presence of standard physiological serum lipids. Depletion of serum lipids resulted in a statistically significant reduction in gene-knockdown efficiency (P < 0.001), confirming that circulating lipoproteins play a direct, functional role in mediating SIL204 cellular uptake and oncogenic silencing.

Importantly, the addition of exogenous human low-density lipoprotein (LDL) did not alter gene-silencing potency compared to complete serum alone. This observation indicates that endogenous levels of circulating lipoproteins present under normal physiological conditions are already sufficient to support efficient cellular uptake and target knockdown, eliminating the need for external lipid supplementation or artificial carrier vehicles.

The findings emerge as Silexion continues translational characterization of SIL204 alongside clinical trial site initiation at Tel Aviv Sourasky Medical Center and regulatory clearances in Germany. Additional preclinical evaluations, including in vivo pharmacokinetic (PK), cellular uptake kinetics, and tissue biodistribution studies, are currently underway to further characterize the correlation between lipoprotein association, LDLR pathway engagement, systemic exposure, and anti-tumor activity in vivo.

According to Silexion's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 14, 2026, Silexion cautions that these forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements.